Clinical outcome after switching therapy from ranibizumab and/or bevacizumab to aflibercept in central retinal vein occlusion. [electronic resource]
Producer: 20160419Description: 150-6 p. digitalISSN:- 1423-0259
- Aged
- Aged, 80 and over
- Angiogenesis Inhibitors -- therapeutic use
- Bevacizumab -- therapeutic use
- Drug Substitution
- Female
- Humans
- Intravitreal Injections
- Macular Edema -- drug therapy
- Male
- Ranibizumab -- therapeutic use
- Receptors, Vascular Endothelial Growth Factor -- therapeutic use
- Recombinant Fusion Proteins -- therapeutic use
- Retina -- pathology
- Retinal Vein Occlusion -- complications
- Retrospective Studies
- Tomography, Optical Coherence
- Treatment Outcome
- Vascular Endothelial Growth Factor A -- antagonists & inhibitors
- Visual Acuity -- drug effects
No physical items for this record
Publication Type: Journal Article; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.